Ultragenyx Pharmaceutical (NASDAQ:RARE) has been given a consensus recommendation of “Buy” by the twenty-two ratings firms that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, six have issued a hold rating and fourteen have issued a buy rating on the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $69.81.
Several research analysts have commented on the company. BidaskClub downgraded Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a research note on Friday, February 9th. Zacks Investment Research cut Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a report on Tuesday, January 30th. Morgan Stanley reaffirmed an “equal weight” rating and issued a $60.00 price target (up previously from $57.00) on shares of Ultragenyx Pharmaceutical in a report on Wednesday, February 21st. Credit Suisse Group initiated coverage on Ultragenyx Pharmaceutical in a report on Wednesday, January 17th. They issued an “outperform” rating and a $67.00 price target on the stock. Finally, Bank of America raised their price target on Ultragenyx Pharmaceutical from $60.00 to $61.00 and gave the company a “buy” rating in a report on Wednesday, February 21st.
NASDAQ RARE traded up $0.86 during trading hours on Thursday, hitting $54.68. The company had a trading volume of 896,999 shares, compared to its average volume of 554,006. Ultragenyx Pharmaceutical has a 52 week low of $41.67 and a 52 week high of $71.99. The company has a market cap of $2,635.06, a P/E ratio of -7.29 and a beta of 1.82.
Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its earnings results on Tuesday, February 20th. The biopharmaceutical company reported ($2.27) EPS for the quarter, missing the consensus estimate of ($2.00) by ($0.27). The business had revenue of $2.41 million during the quarter, compared to analyst estimates of $0.75 million. During the same period in the prior year, the company posted ($1.75) EPS. equities research analysts predict that Ultragenyx Pharmaceutical will post -6.03 EPS for the current fiscal year.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Candriam Luxembourg S.C.A. raised its holdings in shares of Ultragenyx Pharmaceutical by 23.3% during the 4th quarter. Candriam Luxembourg S.C.A. now owns 74,000 shares of the biopharmaceutical company’s stock valued at $3,432,000 after buying an additional 14,000 shares in the last quarter. Paloma Partners Management Co purchased a new position in shares of Ultragenyx Pharmaceutical during the 4th quarter valued at about $580,000. Swiss National Bank raised its holdings in shares of Ultragenyx Pharmaceutical by 4.0% during the 4th quarter. Swiss National Bank now owns 69,952 shares of the biopharmaceutical company’s stock valued at $3,244,000 after buying an additional 2,700 shares in the last quarter. Prosight Management LP purchased a new position in shares of Ultragenyx Pharmaceutical during the 4th quarter valued at about $2,069,000. Finally, Cornerstone Capital Management Holdings LLC. increased its stake in Ultragenyx Pharmaceutical by 11.7% in the 4th quarter. Cornerstone Capital Management Holdings LLC. now owns 19,098 shares of the biopharmaceutical company’s stock worth $885,000 after purchasing an additional 2,000 shares during the period. 87.19% of the stock is currently owned by institutional investors.
WARNING: “Ultragenyx Pharmaceutical (RARE) Receives $69.13 Consensus Price Target from Brokerages” was published by Zolmax and is owned by of Zolmax. If you are viewing this piece of content on another site, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://zolmax.com/investing/ultragenyx-pharmaceutical-rare-receives-69-13-consensus-price-target-from-brokerages/2112541.html.
About Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologics product candidate includes Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII.
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.